Pharmafile Logo
Pharmafocus logo
Advanced Search

Merck

Showing 15 posts of 363 posts found.

Merck chief defends ‘bumpy’ 2011

January 6, 2012
Sales and Marketing Kenneth Frazier, Merck

Kenneth Frazier has defended his company’s ‘bumpy’ performance in 2011, and has highlighted key drugs for investors to watch. Frazier …

News
Victrelis picture

Merck and Roche begin combination hep C trial

December 16, 2011
Research and Development, Sales and Marketing Copegus, Merck, Pegasys, Roche, Victrelis

Merck and Roche have started clinical trials to investigate combinations of their hepatitis C drugs. The first trial is designed …

News
k_frazier_landscape_web

Frazier defends R&D investment and attacks price pressure

December 14, 2011
Research and Development, Sales and Marketing Merck, R&D productivity, prices

Merck & Co chief executive Kenneth Frazier has expressed concern that European governments increasingly want to pay unrealistically low prices …

News
daxas_web

NICE rejects Merck’s COPD drug Daxas

December 9, 2011
Sales and Marketing COPD, Daxas, Merck, Nycomed

NICE has not recommended Merck’s COPD drug Daxas and is asking for a new clinical trial to test its effectiveness. …

News
Merck Facebook

Merck and Merck look to settle Facebook naming dispute

November 29, 2011
Medical Communications Facebook, Merck, Merck KGaA

Merck & Co and Merck KGaA looked to have made inroads into their Facebook naming quarrel. Earlier this month Merck …

News

Onglyza cleared for use with insulin

November 29, 2011
Sales and Marketing AstraZeneca, Merck, Onglyza, diabetes, insulin

European regulators have approved a licence extension for Bristol-Myers Squibb and AstraZeneca’s type II diabetes treatment Onglyza. The oral DPP-4 …

News
Vioxx

Merck pays $950 million to settle Vioxx charges

November 23, 2011
Sales and Marketing Department of Justice, Merck, Vioxx, marketing violations, off label marketing

Merck will pay out $950 million and admit that it illegally marketed its painkiller Vioxx in the US. It will …

News

Merck’s vorapaxar fails in late-stage trial

November 15, 2011
ACS, Brilinta, Efient, Merck, Plavix, antiplatelet, vorapaxar

Merck’s novel blood thinner vorapaxar has failed to meet its primary endpoint in a late-stage study.The TRACER trial compared vorapaxar …

News
Merck

Merck highlights updated pipeline

November 11, 2011
Sales and Marketing CETP inhibitor, Merck, cholesterol, pipeline

Merck has showcased its most promising drug candidates, and says it expects to make eight US filings in the next …

News

Core products boost Merck’s results

October 31, 2011
Medical Communications, Sales and Marketing Gardasil, Merck, Victrelis

Sales of core products and favourable exchange rates have helped Merck grow its revenue in a tough environment.  Worldwide sales …

News

Abbott spin-off could attract mega merger

October 21, 2011
Research and Development, Sales and Marketing Abbott, Bayer, Humira, Merck, Roche

Abbott’s new spin-off pharma firm could attract a lot of attention from big pharma looking to sure up their portfolios. …

News

Fresh scrutiny for new diabetes drugs

September 15, 2011
Sales and Marketing Byetta, GLP-1, Januvia, Merck, Novo Nordisk, Victoza, diabetes

Merck’s Januvia and Lilly’s Byetta face renewed safety questions this week as the European Association for the Study of Diabetes …

News

Merck signs major deal with China’s Simcere

July 21, 2011
Sales and Marketing Merck, Simcere, emerging markets

Merck is to establish a joint venture with China’s Simcere focused on serving China’s rapidly expanding health care needs by …

News

Roche and Merck collaborate on personalised cancer tests

June 8, 2011
Research and Development Merck, Roche, personalised medicine

Roche has signed a deal to develop diagnostic tests for products in Merck’s oncology pipeline, in a bid to make …

News
Merck & Co's Victrelis (boceprevir)

Merck and Roche sign hepatitis C co-promotion deal

May 18, 2011
Medical Communications, Sales and Marketing Merck, Roche, hepatitis C

Merck & Co and Roche have signed an agreement that will see them co-promote each other’s hepatitis C drugs in …

News
The Gateway to Local Adoption Series

Latest content

Just – Evotec given Gates Foundation grant to increase global biotherapeutics access

January 8, 2026

Johnson & Johnson submits robotic surgical system for De Novo classification

January 8, 2026

EA Pharma announces phase 3 trial for new schizophrenia treatment in Japan

January 7, 2026

Eleva appoints Erich Rajkovic as Chief Business Officer

January 7, 2026

MedPharm announces US FDA inspection of North Carolina manufacturing facility

January 6, 2026